Clinical Trial News

Dupixent's dominance in the atopic dermatitis market is waning due to new treatments like Adbry, Cibinqo, and Rinvoq. Dermatologists estimate advanced systemic treatments now serve two-fifths of adult AD patients, highlighting the need for new options. Efficacy attributes like itch reduction and mechanism of action are key differentiators, with nemolizumab and lebrikizumab expected to further shift preferences away from Dupixent.

Christine D’Addario, 41, diagnosed with stage IIB triple-negative breast cancer, found support through Manhasset Women’s Coalition Against Breast Cancer. She opted for a clinical trial involving pembrolizumab and chemotherapy, which led to a lumpectomy and remission, allowing her to maintain a healthy appearance and continue her art, inspiring others.

Apple's 'It’s Glowtime' event to unveil iPhone 16 with AI capabilities, Summit Therapeutics shares soar on positive lung cancer drug trial results, Palantir jumps on S&P 500 inclusion news, Boeing stock surges after union deal, and futures point to higher open for major indexes.

GRAIL, Inc. (GRAL) develops multi-cancer early detection tests using NGS technology, with its Galleri test detecting over 50 cancer types from a blood sample. The company aims to secure FDA approval for Galleri, which could enhance market acceptance and insurance coverage, potentially improving patient outcomes through early detection. GRAL is currently a standalone company after being spun off from Illumina, with a focus on cost-cutting measures and FDA approval to become a sustainable entity.

FDA clears tubeless insulin patch pump for type 1 and type 2 diabetes, featuring a 300 U insulin reservoir for up to 3 days use.

Researchers analyzed vaginal swabs from VOICE study participants to identify 14 BV-associated bacterial taxa and 6 inflammatory proteins linked to increased HIV risk. High concentrations of these markers, particularly IP-10, distinguished women at highest risk. The study also found that Lactobacillus crispatus was associated with protection against HIV. Future prevention efforts could involve testing for high-risk bacteria and exploring antibiotic or probiotic treatments.

Genus PLC reported FY 2024 revenue of GBP669 million and adjusted operating profit of GBP78.1 million, with strategic progress in porcine and bovine businesses. Despite profit declines, the company maintained a steady dividend and expects significant growth in FY 2025, anticipating FDA approval for its gene-edited pig in 2025.

Avacta Group to present updated Phase 1a trial data of AVA6000 at 2024 ESMO Congress in Barcelona, focusing on FAP-positive solid tumours. AVA6000 is a doxorubicin peptide drug conjugate targeting the tumour microenvironment.

Psyence Biomedical completes first site initiation visit for Phase IIb study of nature-derived psilocybin for Adjustment Disorder in Palliative Care, with patient screening to start soon and first subject expected in October.

VCU Health’s Neurosurgery Department is part of a clinical study aiming to improve recovery and reduce complications for NPH patients using the CereVasc® eShunt® Implant, which can be delivered via a tiny leg incision. VCU Health, selected for its reputation in NPH treatment, is one of twelve U.S. hospitals in the trial.